Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction

Author： Kendirci Muammer   Bivalacqua Trinity J   Hellstrom Wayne JG  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.5, Iss.4, 2004-04, pp. : 923-932

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Potency and selectivity of vardenafil: a phosphodiesterase Type 5 inhibitor

By Sommer Frank  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 1, Iss. 2, 2005-08 ,pp. : 295-301

Informa Healthcare

Access to resources Recommend Favorite

Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction

By Limin Ma   Johnsen Niels   Hellstrom Wayne JG  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 11, 2010-11 ,pp. : 1427-1437

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction

By Dorsey Philip   Keel Christopher   Klavens Meghan   Hellstrom Wayne JG  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 7, 2010-05 ,pp. : 1109-1122

Informa Healthcare

Access to resources Recommend Favorite

An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors

By Bruzziches Roberto  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 10, 2013-07 ,pp. : 1333-1344

Informa Healthcare

Access to resources Recommend Favorite

Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction

By Kuan James   Brock Gerald  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 11, 2002-11 ,pp. : 1605-1613

Informa Healthcare

Access to resources Recommend Favorite